TRDA Stock Price, Entrada Therapeutics, . Quote, Chart

Market Summary

USD13.56+0.31

Market Closed

2.34%

TRDA Alerts

1 major insider buys recently.

TRDA Stock Price

View Fullscreen

TRDA RSI Chart

TRDA Valuation

Market Cap

455.6M

Price/Earnings (Trailing)

-68.16

Price/Sales (Trailing)

3.53

Price/Free Cashflow

3.4

TRDA Price/Sales (Trailing)

TRDA Profitability

Return on Equity

-2.76%

Return on Assets

-1.42%

Free Cashflow Yield

29.45%

TRDA Fundamentals

TRDA Revenue

Revenue (TTM)

129.0M

Rev. Growth (Qtr)

140.7%

TRDA Earnings

Earnings (TTM)

-6.7M

Earnings Growth (Yr)

61.25%

Earnings Growth (Qtr)

-126.91%

Breaking Down TRDA Revenue

Last 7 days

9.7%

Last 30 days

-2.3%

Last 90 days

-7.9%

Trailing 12 Months

10.8%

How does TRDA drawdown profile look like?

TRDA Financial Health

Current Ratio

2.33

TRDA Investor Care

Shares Dilution (1Y)

6.25%

Diluted EPS (TTM)

-0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	129.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Entrada Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	kim peter s	bought	35,289	13.573	2,600	-
Mar 28, 2024	kim peter s	bought	20,793	13.7526	1,512	-
Mar 26, 2024	kim peter s	bought	37,509	13.6397	2,750	-
Mar 25, 2024	kim peter s	bought	42,472	13.356	3,180	-
Mar 22, 2024	kim peter s	bought	42,900	13.759	3,118	-
Mar 21, 2024	kim peter s	bought	9,317	13.2353	704	-
Mar 20, 2024	kim peter s	bought	14,280	12.6604	1,128	-
Mar 19, 2024	kim peter s	bought	11,397	12.6633	900	-
Mar 15, 2024	wentworth kory james	acquired	18,900	2.1	9,000	chief financial officer
Mar 06, 2024	wentworth kory james	sold	-50,285	12.3067	-4,086	chief financial officer

Which funds bought or sold TRDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	sold off	-100	-164,089	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	56.00	56.00	-%
Apr 29, 2024	Allspring Global Investments Holdings, LLC	added	427	166,971	209,192	-%
Apr 25, 2024	NEW YORK STATE TEACHERS RETIREMENT SYSTEM	new	-	27,000	27,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-3.88	-169,082	1,567,170	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.36	-18,000	10,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-8,303	176,462	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	567	567	-%

Are Funds Buying or Selling TRDA?

Are funds buying TRDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TRDA

No. of Funds

TRDA Alerts

1 major insider buys recently.

Unveiling Entrada Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	roche finance ltd	8.2%	2,744,120	SC 13G/A
Feb 14, 2024	redmile group, llc	3.8%	1,283,735	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	9.0%	3,009,673	SC 13G/A
Feb 14, 2023	redmile group, llc	5.9%	1,854,108	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	9.6%	3,014,377	SC 13G/A
Feb 06, 2023	wellington management group llp	3.22%	1,010,351	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	6.4%	2,020,637	SC 13G
Feb 14, 2022	redmile group, llc	6.3%	1,954,420	SC 13G
Feb 14, 2022	roche finance ltd	9.0%	2,813,525	SC 13G
Feb 08, 2022	mrl ventures fund llc	5.6%	1,739,768	SC 13G

Recent SEC filings of Entrada Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 26, 2024	144	Notice of Insider Sale Intent
Apr 25, 2024	144	Notice of Insider Sale Intent
Apr 24, 2024	144	Notice of Insider Sale Intent
Apr 23, 2024	144	Notice of Insider Sale Intent
Apr 19, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Entrada Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Entrada Therapeutics, Inc. News

Latest updates

Entrada Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1
Revenue	-4.3%	42.00	44.00	18.00	25.00
Operating Expenses	24.3%	37.00	30.00	34.00	31.00
S&GA Expenses	14.9%	9.00	8.00	8.00	8.00
R&D Expenses	27.5%	28.00	22.00	26.00	23.00
Income Taxes	207.7%	19.00	-17.40	14.00	4.00
Net Income	-126.9%	-9.54	35.00	-25.93	-6.67
Net Income Margin	-Infinity%	-0.05*	-	-	-
Free Cashflow	80.8%	-4.99	-25.94	-36.61	202

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-3.3%	469	485	494	476	252	274	296	317	306	132	44.00
Current Assets	-3.5%	370	383	390	434	210	235	254	273	299	124	40.00
Cash Equivalents	30.3%	68.00	52.00	80.00	228	45.00	57.00	95.00	89.00	291	122	39.00
Net PPE	1.3%	11.00	11.00	11.00	9.00	8.00	7.00	8.00	7.00	6.00	6.00	3.00
Liabilities	-4.8%	227	238	287	246	40.00	41.00	40.00	39.00	7.00	7.00	3.00
Current Liabilities	-4.0%	159	165	126	148	22.00	22.00	18.00	15.00	7.00	7.00	3.00
Shareholder's Equity	-1.7%	242	247	207	230	213	233	256	277	299	-	-
Retained Earnings	-5.2%	-195	-185	-220	-194	-188	-163	-138	-115	-93.67	-75.22	-42.51
Additional Paid-In Capital	1.1%	437	433	429	425	403	400	397	394	392	3.00	1.00
Shares Outstanding	0.3%	33.00	33.00	33.00	33.00	31.00	31.00	31.00	31.00	31.00	1.00	1.00
Float	-	-	-	431	-	-	-	274	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	83.6%	-4,013	-24,492	-35,091	203,399	-27,304	-27,482	-18,009	-20,991	-20,541	-14,075	-7,910	-8,336	-	-
Share Based Compensation	13.1%	3,841	3,396	3,119	2,755	2,882	2,707	2,512	1,794	1,458	578	326	164	-	-
Cashflow From Investing	609.6%	19,043	-3,737	-113,257	-40,444	18,792	-10,134	24,225	-181,533	-1,322	-806	-1,544	-908	-	-
Cashflow From Financing	87.5%	690	368	443	19,536	358	60.00	11.00	50.00	190,755	106	215	116,385	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TRDA Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 129,013
Operating expenses:
Research and development	99,884	$ 66,609
General and administrative	32,291	30,639
Total operating expenses	132,175	97,248
Loss from operations	(3,162)	(97,248)
Other income:
Interest and other income	15,218	2,632
Total other income	15,218	2,632
Income (loss) before income taxes	12,056	(94,616)
Income tax	(18,741)	0
Net loss	$ (6,685)	$ (94,616)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.20)	$ (3.02)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.20)	$ (3.02)
Weighted-average common shares outstanding, basic (in shares)	33,050,319	31,293,312
Weighted-average common shares outstanding, diluted (in shares)	33,050,319	31,293,312
Other comprehensive loss:
Unrealized income (loss) on marketable securities, net of tax of $0	$ 2,252	$ (2,057)
Total other comprehensive income (loss)	2,252	(2,057)
Total comprehensive loss	$ (4,433)	$ (96,673)

TRDA Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 67,602	$ 45,157
Marketable securities	284,367	143,555
Collaboration receivable	5,878	0
Prepaid expenses and other current assets	11,924	21,163
Total current assets	369,771	209,875
Property and equipment, net	11,191	7,681
Restricted cash	3,950	3,950
Right-of-use assets, operating leases	81,490	25,340
Other non-current assets	2,790	5,210
Total assets	469,192	252,056
Current liabilities:
Accounts payable	3,277	5,990
Accrued expenses and other current liabilities	11,325	7,576
Income taxes payable	4,024	0
Operating lease obligations, current portion	7,909	8,406
Deferred revenue, current portion	132,261	0
Total current liabilities	158,796	21,972
Operating lease obligations, net of current portion	60,321	17,530
Deferred revenue, net of current portion	7,715	0
Total liabilities	226,832	39,502
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, par value $0.0001; 150,000,000 shares authorized; 33,461,771 shares issued and 33,437,296 shares outstanding as of December 31, 2023 and 31,448,508 shares issued and 31,394,767 shares outstanding as of December 31, 2022	3	3
Additional paid‑in capital	437,132	402,893
Accumulated other comprehensive income (loss)	195	(2,057)
Accumulated deficit	(194,970)	(188,285)
Total stockholders’ equity	242,360	212,554
Total liabilities and stockholders’ equity	$ 469,192	$ 252,056

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

CEO	Mr. Dipal Doshi
WEBSITE	entradatx.com
INDUSTRY	Biotechnology
EMPLOYEES	131

Entrada Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Entrada Therapeutics, Inc.? What does TRDA stand for in stocks?

TRDA is the stock ticker symbol of Entrada Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Entrada Therapeutics, Inc. (TRDA)?

As of Thu May 02 2024, market cap of Entrada Therapeutics, Inc. is 455.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TRDA stock?

You can check TRDA's fair value in chart for subscribers.

What is the fair value of TRDA stock?

You can check TRDA's fair value in chart for subscribers. The fair value of Entrada Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Entrada Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TRDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Entrada Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TRDA is over valued or under valued. Whether Entrada Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Entrada Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TRDA.

What is Entrada Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, TRDA's PE ratio (Price to Earnings) is -68.16 and Price to Sales (PS) ratio is 3.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TRDA PE ratio will change depending on the future growth rate expectations of investors.